{"name":"Privo Technologies","slug":"privo-technologies","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPRjd6d2d4Vnl0dlB3Rk1lbXN5NWxqaFljLTlrdGVZX2UtRjBBMnBMdzJwdkV5RUJQalRoNWxFbE5Sek5FZHpuazFhaEliQk5EZzVJQm5UbVhZdEF1bTF6LUtLcWhDRHVuaVJhNVFLNlM5OWdIVV9zX2lfMDEtWG55em1ldGkxNmNQR1Z2Nlo5M0ZfSFk?oc=5","date":"2026-04-08","type":"trial","source":"openPR.com","summary":"Human Papillomavirus Associated Cancer Clinical Trial - openPR.com","headline":"Human Papillomavirus Associated Cancer Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxQOTN2SlNJZUx2Ul9KLTNzVXlrY1pub1Z2VEx0aEkxVzdUb0Y3UnhoVHpxOEhlQVlNN2hQbjJJc3VINTVHZVhfV2Q1S2xyb21RXzRDNml3bFZ4NGV4Uzc1TjdfVWhHNXE2YXI5S19BNW5rbDJabjA1QkNGMW4yTWx2Ulc0S2NPNnVJMkNpbVViSTJKMXNjd25FYWdUaHdnVkVWNWxHQjFVYVRvVFc3MXNleEl2eHlWXzdoQWo4VlF5SldoQ01xakdjc1dTNTJ0TTRoaVlOMnRWQXdtUEltR0JSbDFCcW1KdWFUMUZxalI0cHNvT0xibl9KSnNjNVFBRWlLZEhTeEJPYjZuZE1NZlF6VFg0Q0xPV2pELWc?oc=5","date":"2026-01-23","type":"pipeline","source":"PR Newswire","summary":"/C O R R E C T I O N -- Privo Technologies/ - PR Newswire","headline":"/C O R R E C T I O N -- Privo Technologies/","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxQWGY4NUxmNDcyYnVhbE81bEJzaExLdlJiTWNXMGN5NTJ4ZDZXeUE2c1JJSXo5VkNGVlRUSGtTX1BQbnk4TFZhZmpQMkNHRkZmOTRFdzA0S19GRjBtejd5Rlc1RDJacHRubndHaFJtbWp1S0VHamw0NFdDdDhfRnZCX0RpLVdSUzBGTWZMMnBJNlRqLW5vMHdKQUNXV0dSOFM1Smw0cC1JRWZaNkM3YktJQ2paRWZySDVHLXI1SW1RaU5tenpqVmNOWElMUmhqMnpCSTVNaHBnYmk3OFdUZ3I3Slh2OWc1ck1WX3VqV3lFX1dZUml5NnpmNUUyNUVkWU1JM2l6enBORU5OS1FyQnZIMjZMWXgxUk84RkRXVmFYLVlDV01sd0tUOUVXNHNsdXNrbmViTA?oc=5","date":"2025-12-10","type":"trial","source":"PR Newswire","summary":"Privo Technologies Begins Dosing PRV131 in Arm 3 Of Clinical Study CLN-004, A First-In-Class Cisplatin Intratumoral Injectable Targeting Oral Cavity Cancer - PR Newswire","headline":"Privo Technologies Begins Dosing PRV131 in Arm 3 Of Clinical Study CLN-004, A First-In-Class Cisplatin Intratumoral Inje","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AJBVV95cUxOU3F6TE8ydTg1YlBfbURsLXg1RzlhbVFQNkpBekZuSEUySlVxSUs4UUhnVGlZUmZ1anEzNklpTzhoRHV0TjNuLXpZclFra1VYb1J1ZDluOHJydFlkd1VDMzZYam90TWFFQ2hIODdFckZVRGo3YXJKcWhNZzVvVUxOMUFXOGNuMFJFVzAwUExzXzRnVHFUdGh3WURBN2VHcVBJbzdVMWducHM4RWQ2Yy04UXloODc0eWpLWU12aWxCenUydU80c1J3V1J2TlRXcjJIYW9EQWQxRWdmN1BVSE82ZjJ2RHd6SG0wMFZRWEducFJub0hURmdUaWFRaDlVQzlReUg2X3QwcHFSOXcyWGxPamRWLVhFeFZDN0laRlB5d012Mkt3MmtRT1A3VVV0YmlidnUxOU02QWE1YjdoUENTZUhtVUlhaVVVU2FFSXdfQU5kaGVJU29pNUZsMGw?oc=5","date":"2025-11-17","type":"trial","source":"PR Newswire","summary":"PRV111, in Development as the First Non-Surgical Therapy for Early-Stage Non-Invasive Oral Cancer and High-Grade Dysplasias, Meets Its Primary Efficacy Endpoint in Ongoing Phase 2/3 Trial - PR Newswir","headline":"PRV111, in Development as the First Non-Surgical Therapy for Early-Stage Non-Invasive Oral Cancer and High-Grade Dysplas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxOaVZsdm5IZ05VWHh0ZHo2OWYzTXE0SGZXbWc1eHVkT0hpb2tCRmJmekJfb3F3MEhOWk44U3N0LWZLV1FzRmY4YWRqMm5zeklFQUw3Z0tIUmttNXBLTmxpdkw0R3pCdzZVbk92eXlWSHpfWTl6alJfcmlpZjdRNmRmbzNWSl9fM3hlMkozOUhrdWY2SzJ6c0NPR2djUTIxMGFaV3B0cloyTkJ3ZVhiNzRZSjI3UTlDakU1a2VqdWlqdUJwZWg2UWdIQm9MWS0tS0dKcjJIRTYySG1uR1VEZE5jWnZGVWlVMkNrSEtROXo3dWxYdURBaUYwQmxmcU45NW1KLUhVdEJ0UVNENEFoRVE?oc=5","date":"2025-10-14","type":"trial","source":"PR Newswire","summary":"Privo Technologies Completes Phase 2 Run-In in PRV111 Oral Cancer Trial, Highlighting Potential to Spare Patients from Surgery - PR Newswire","headline":"Privo Technologies Completes Phase 2 Run-In in PRV111 Oral Cancer Trial, Highlighting Potential to Spare Patients from S","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQRC1NdlRBZWhKVk1oMEF6YWg2Z09oTjV6VUdRWUpGTUY4bFkxZXZLcXNVcElxcXUxa3ZrVktSZWd6ZFJ3Y1RVWFNmcUI4ZjdyY3pNVFI4T190TXVQYlRsc3BDRVlJSTdqMDJaRVpMOGo4cWZncnR4Z25yOFYtUVpTTGN3ZTNmR2dHQk5RdmVOa1k4Rzg4ZnQ2TDdqUlduWkFEVFgyVzhSMzZUN0pkNGRYaEE4Q3BlbHEtMVE0clQ3MWdKOGZDdlVfTDJDNkpLdUphMmdQNg?oc=5","date":"2025-04-28","type":"trial","source":"PR Newswire","summary":"Privo Technologies Expands CLN-004 Clinical Trial Across Leading U.S. Cancer Centers - PR Newswire","headline":"Privo Technologies Expands CLN-004 Clinical Trial Across Leading U.S. Cancer Centers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNUTVPUDFjOV9pdWFleUdrVXlHZEktWXg1WldsSGxsZ2RDdmZFeGhRdHpNV2hGWFF1bDBKeDB2cUNmc041QnJ1a1NWdGp5Nk5sN3lPMEdaNnBCV1IzdzE0dmpmX0RSQVJ1c3M3WUFYTGs1eWxIY1VhSnJ4XzZleml4Uk1uZG9DTE5rbjFwUE9HNGM4QkVwMS1xMkszLU9XNGE5TXNhdWpPNA?oc=5","date":"2025-03-27","type":"pipeline","source":"DVM360","summary":"Human biopharmaceutical expands into veterinary medicine with new subsidiary - DVM360","headline":"Human biopharmaceutical expands into veterinary medicine with new subsidiary - DVM360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9zVzQ5RUVUQjhLN0dLUEdhMkVLOW9rZ2FpNHU3X1dZX1lmWkM4X1RveHdabWxLeWdCaklJLWE3eTc0OFlvbUFwYWM1cW5IZUVHaEF0UktESmdrRWVteERJ?oc=5","date":"2022-08-17","type":"pipeline","source":"nature.com","summary":"A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer - nature.com","headline":"A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patient","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQd0d3VlFNVTY1c3lSYkJLSzE5MW9iOVgxRTk3b1l6aGh5NEpZZUJERnNiRWtCakMtQTVwdXBHZEZLb09ubnVYMjVEeXZZUWdKaGVJdXBXbWRSSjdVcldaUHh4ZWJRYUJmZkVrZkdEMEUxTktKdGZrejZNOTNNTWU3MGViWF9oSlc4R1FwcW1WTWdaeWlyakVVVVFJWVJlME9vM3pYcTJxR1ZfSVp2QzlWSkczX0Z2MTBrSElacV93RDBKQ0VDWDFpREw4bw?oc=5","date":"2018-10-24","type":"trial","source":"PR Newswire","summary":"Clinical Trial Expected to Yield Promising Results for Oral Cancer Patients - PR Newswire","headline":"Clinical Trial Expected to Yield Promising Results for Oral Cancer Patients","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}